Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.4% on Analyst Downgrade

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares were down 4.4% during trading on Wednesday after KeyCorp lowered their price target on the stock from $12.00 to $10.00. KeyCorp currently has an overweight rating on the stock. Recursion Pharmaceuticals traded as low as $7.04 and last traded at $7.16. Approximately 4,653,415 shares changed hands during trading, a decline of 70% from the average daily volume of 15,549,441 shares. The stock had previously closed at $7.49.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.75.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total transaction of $76,351.49. Following the transaction, the director now owns 7,089,007 shares of the company’s stock, valued at $47,283,676.69. This trade represents a 0.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,341 shares of company stock valued at $393,490. Insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Recursion Pharmaceuticals by 6.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock worth $7,751,000 after buying an additional 67,464 shares in the last quarter. Franklin Resources Inc. increased its position in Recursion Pharmaceuticals by 58.9% in the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock valued at $127,000 after acquiring an additional 7,027 shares during the period. Sanctuary Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $89,000. Finally, Geode Capital Management LLC boosted its position in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after acquiring an additional 656,003 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $2.69 billion, a P/E ratio of -4.50 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a 50 day moving average price of $6.94 and a 200-day moving average price of $7.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.43) EPS. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.